New serum tumor markers S100, TFF3 and AIF-1 and their possible use in oncogynecology

Authors: M. Maděrka;  R. Pilka;  D. Neubert;  J. Hambálek
Authors‘ workplace: Porodnicko-gynekologická klinika LF UP a FN, Olomouc, přednosta prof. MUDr. R. Pilka, Ph. D.
Published in: Čes. Gynek.2019, 84, č. 4 s. 303-308


Objective: To review a literature about possible new blood serum gynecologic tumor markers, S100 proteins family, trefoil factor 3 and AIF-1.

Design: Literature review.

Setting: Department of Obstetrics and Gynecology, Faculty of Medicine, Palacky University and University Hospital in Olomouc.

Methods: Literature review of articles published in PubMed database till January 2019.

Results: The association of S100A2, S100A4, S100A6, S100A7, S100A8, S100A9 and S100A11 with breast carcinoma has been demonstrated in the literature. The association of S100A2, S100A4, S100A6, S100A7A, S100A10, S100A14, S100A16, S100B, S100P (up-regulation associated with a lower survival) and S100A1, S100A13, S100A5, S100A13 and S100G proteins (up-regulation associated with a better survival) have been demonstrated in ovarian cancer patients. Cervical carcinoma has been shown to be associated with the S100A9 protein. TFF3 association with endometrial cancer, breast cancer (worse prognosis) and ovarian cancer (better prognosis) has been demonstrated. AIF-1 has been shown to increase expression in cervical cancer.

Conclusion: Tumor markers can be a very useful tool for patient management when used appropriately. Further research in this area and the search for new tumor markers, including S100, TFF3 and AIF-1, are needed. In future studies, scientists should focus not only on one time point, but assess the trend of the tumor markers for a specific time axis.


oncogynecology – tumor markers – S100 – TFF3 – AIF-1


1. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. J Clin Oncol.

2. AIF1 allograft inflammatory factor 1 [Homo sapiens (human)] – Gene – NCBI.

3. Bai, Y., Li, L-D., Li, J., et al. Prognostic values of S100 family members in ovarian cancer patients. BMC Cancer 18.

4. Bignotti, E., Ravaggi, A., Tassi, RA., et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer, 1999, p. 768–773.

5. Bruix, J., Sherman, M. American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatol Baltim Md, 2011, p. 1020–1022.

6. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. PubMed – NCBI.

7. Candidates for Tumor Markers of Cervical Cancer Discovered by Proteomic Analysis.

8. Cardoso, F., Costa, A., Norton, L., et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol Off J Eur Soc Med Oncol, 2005, 25, p. 1871–1888.

9. Cardoso, F., Costa, A., Norton, L., et al. European School of Oncology, European Society of Medical Oncology ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast Edinb Scotl, 2004, 23, p. 489–502.

10. Chen, Y., Chen, C., Yang, B. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett, 2011, 302, p. 63–68.

11. Ducreux, M., Cuhna, A., Caramella, C., et al. ESMO Guidelines Committee Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol, 2015, 5, p. 56–68.

12. Hoellen, F., Kostara, A., Karn, T., et al. Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters. Mol Clin Oncol, 2016, 5, p. 422–428.

13. Ito, D., Imai, Y., Ohsawa, K., et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res, 1999, 57, p. 1–9.

14. Kennedy, R., Gorski, J., Quinn, J., et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res, 2005, 65, p. 10265–10272.

15. Lau, W., Pandey, V., Kong, X., et al. Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2. PloS One, 2016, 10, p. e0141947.

16. Menon, U., Ryan, A., Kalsi, J., et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol Off J Am Soc Clin Oncol, 2015, 33, p. 2062–2071.

17. Meyerhardt, J., Mangu, P., Flynn, P., et al. American Society of Clinical Oncology Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol Off J Am Soc Clin Oncol, 2015, 31, p. 4465–4470.

18. Molina, R., Marrades, R., Augé, J., et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med, 2016, 193, p. 427–437.

19. Neubert, D., Ondrová, D., Hambálek J., et al. Elevated levels of TFF3 in endometrial cancer patients. Ces Gynek, 2018, 83, p. 109–114.

20. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor PNAS.

21. Rafii, S., Lyden, D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol, 2006, 8, p. 1321–1323.

22. S100A9 regulates cisplatin chemosensitivity of squamous cervical cancer cells and related mechanism.

23. Sedaghat, F., Notopoulos, A. S100 protein family and its application in clinical practice. Hippokratia, 2008, 12, p. 198–204.

24. Serum S100A6 Concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.

25. Sturgeon, C., Duffy, M., Stenman, U., et al. National Academy of Clinical Biochemistry National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem, 2008, 54, p. e11-79.

26. Therasse, P., Arbuck, S., Eisenhauer, E. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92, p. 205–216.

27. Thim, L., Wöldike, H., Nielsen, P., et al. Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry, 1995, 34, p. 4757–4764.

28. Tian, Y., Jain, S., Kelemen, S., et al. AIF-1 expression regulates endothelial cell activation, signal transduction, and vasculogenesis. Am J Physiol Cell Physiol 2009, 296, p. C256–C266.

29. Verslype, C., Rosmorduc, O., Rougier, P., et al. ESMO Guidelines Working Group Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol, 2012, 23, Suppl. 7, p. vii41-48.

30. Watano, K., Iwabuchi, K., Fujii, S., et al. Allograft inflammatory factor-1 augments production of interleukin-6, -10 and -12 by a mouse macrophage line. Immunology, 2001, 104, p. 307.

31. Xiao, P., Ling, H., Lan, G., et al. Trefoil factors: Gastro­intestinal-specific proteins associated with gastric cancer. Clin Chim Acta Int J Clin Chem, 2015, 450, p. 127–134.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account